Celgene inks $500M-plus deal with ADC developer Sutro

Celgene ($CELG) has turned to the upstart antibody-drug conjugate developers at Sutro Biopharma. The drugmaker promises a package of more than $500 million in upfront fees, an equity stake, R&D support and milestones in exchange for some fine-tuned products. Report